Mitochondrial transcription factor a and mitochondrial genome as molecular targets for cisplatin-based cancer chemotherapy

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 19836-19850

  Kohno, Kimitoshi ^a   Wang, Ke Yong ^b   Takahashi, Mayu ^b   Kurita, Tomoko ^b   Yoshida, Yoichiro ^c   Hirakawa, Masakazu ^d   Harada, Yoshikazu ^b   Kuma, Akihiro ^b   Izumi, Hiroto ^b   Matsumoto, Shinji ^a  

^a Asahi Matsumoto Hospital Sumoto   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Cancer chemotherapy; Cisplatin; mtDNA; mtTFA; Prognosis

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ADENOSINE TRIPHOSPHATASE; CALCIUM ION; CISPLATIN; CYTOCHROME C'; DNA; FLUOROURACIL; FOLINIC ACID; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; NUCLEAR FACTOR I; OXALIPLATIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SURVIVIN; THIOREDOXIN 2; TRANSCRIPTION FACTOR CLOCK; Y BOX BINDING PROTEIN 1; ZINC FINGER PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; MITOCHONDRIAL PROTEIN; TRANSCRIPTION FACTOR;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER STAGING; CELL PROLIFERATION; CLINICAL FEATURE; DNA BINDING; DRUG MECHANISM; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; METASTATIC COLORECTAL CANCER; MITOCHONDRIAL GENOME; NONHUMAN; OVERALL SURVIVAL; OXIDATION REDUCTION REACTION; PROTEIN EXPRESSION; REVIEW; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; DNA DAMAGE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; MITOCHONDRION; NEOPLASMS; OXIDATIVE STRESS;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA DAMAGE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEOPLASMS; OXIDATIVE STRESS; TRANSCRIPTION FACTORS;

EID: 84939825681     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160819836     Document Type: Review

References (70)

1. Wallace, D.C. Mitochondria and cancer. Nat. Rev. Cancer 2012, 12, 685-698.
2. Guha, M.; Avadhani, N.G. Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. Mitochondrion 2013, 13, 577-591.
3. Igney, F.H.; Krammer, P.H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277-288.
4. Holohan, C.; van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 2013, 13, 714-726.
5. Cohen, S.M.; Lippard, S.J. Cisplatin: From DNA damage to cancer chemotherapy. Prog. Nucl. Acid Res. Mol. Biol. 2001, 67, 93-130.
6. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4, 307-320.
7. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7, 573-584.
8. Zamble, D.B.; Lippard, S.J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci. 1995, 20, 435-439.
9. Correia, C.; Lee, S.H.; Meng, X.W.; Vincelette, N.D.; Knorr, K.L.; Ding, H.; Nowakowski, G.S.; Dai, H.; Kaufmann, S.H. Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim. Biophys. Acta 2015, 1853, 1658-1671.
10. Frenzel, A.; Grespi, F.; Chmelewskij, W.; Villunger, A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009, 14, 584-596.
11. Lopez, J.; Tait, S.W. Mitochondrial apoptosis: Killing cancer using the enemy within. Br. J. Cancer 2015, 112, 957-962.
12. Orrenius, S.; Gogvadze, V.; Zhivotovsky, B. Calcium and mitochondria in the regulation of cell death. Biochem. Biophys. Res. Commun. 2015, 460, 72-81.
13. Mandic, A.; Viktorsson, K.; Strandberg, L.; Heiden, T.; Hansson, J.; Linder, S.; Shoshan, M.C. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: Two separate pathways in cisplatin-induced apoptosis. Mol. Cell. Biol. 2002, 22, 3003-3013.
14. Linder, S.; Shoshan, M.C. Lysosomes and endoplasmic reticulum: Targets for improved, selective anticancer therapy. Drug Resist. Updat. 2005, 8, 199-204.
15. Xu, Y.; Wang, C.; Li, Z. A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress. Mol. Clin. Oncol. 2014, 2, 3-7.
16. Simran, S.S.; Paul, T.S. Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles’ heel? Nat. Rev. Cancer 2014, 14, 709-721.
17. Chirino, Y.I.; Pedraza, C.J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp. Toxicol. Pathol. 2009, 61, 223-242.
18. Rybak, L.P.; Whitworth, C.A.; Mukherjea D.; Ramkumar, V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear. Res. 2007, 226, 157-167.
19. Torigoe, T.; Izumi, H.; Ishiguchi, H.; Yoshida, Y.; Tanabe, M.; Yoshida, T.; Igarashi, T.; Niina, I.; Wakasugi, T.; Imaizumi, T.; et al.Cisplatin resistance and transcription factors. Curr. Med. Chem. Anticancer Agents 2005, 5, 15-27.
20. Kohno, K.; Uchiumi, T.; Niina, I.; Wakasugi, T.; Igarashi, T.; Momii, Y.; Yoshida, T.; Matsuo, K.; Miyamoto, N.; Izumi, H. Transcription factors and drug resistance. Eur. J. Cancer 2005, 41, 2577-2586.
21. Galluzzi, L.; Vitale, I.; Michels, J.; Brenner, C.; Szabadkai, G.; Harel-Bellan, A.; Castedo, M.; Kroemer, G. Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis. 2014, 5, e1257.
22. Shen, D.W.; Pouliot, L.M.; Hall, M.D.; Gottesman, M.M. Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 2012, 64, 706-721.
23. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31, 1869-1883.
24. Kong, L.R.; Chua, K.N.; Sim, W.J.; Ng, H.C.; Bi, C.; Ho, J.; Nga M.E.; Pang, Y.H.; Ong, W.R.; Soo, R.A.; et al.MEK Inhibition overcomes cisplatin resistance conferred by SOS/MAPK pathway activation in squamous cell carcinoma. Mol. Cancer Ther. 2015, 14, 1750-1760.
25. Crawford, N.; Chacko, A.D.; Savage, K.I.; McCoy, F.; Redmond, K.; Longley, D.B.; Fennell, D.A. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apotosis 2011, 16, 311-320.
26. Nguyen, L.V.; Vanner, R.; Dirks, P.; Eaves, C.J. Cancer stem cells: An evolving concept. Nat. Rev. Cancer 2012, 12, 133-143.
27. Visvader, J.E.; Lindeman, G.J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8, 755-768.
28. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275-284.
29. Nagano, O.; Okazaki, S.; Saya, H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 2013, 32, 5191-5198.
30. Song, I.S.; Jeong, J.Y.; Jeong, S.H.; Kim, H.K.; Ko, K.S.; Rhee, B.D.; Kim, N.; Han, J. Mitochondria as therapeutic targets for cancer stem cells. World J. Stem Cells 2015, 7, 418-427.
31. Kidani, A.; Izumi, H.; Yoshida, Y.; Kashiwagi, E.; Ohmori, H.; Tanaka, T.; Kuwano, M.; Kohno, K. Thioredoxin2 enhances the damaged DNA binding activity of mtTFA through direct interaction. Int. J. Oncol. 2009, 35, 1435-1440.
32. Kohno, K.; Izumi, H.; Uchiumi, T.; Ashizuka, M.; Kuwano, M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003, 25, 691-698.
33. Kashiwagi, E.; Izumi, H.; Yasuniwa, Y.; Baba, R.; Doi, Y.; Kidani, A.; Arao, T.; Nishio, K.; Naito, S.; Kohno, K. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. Cancer Sci. 2011, 102, 382-386.
34. Tanabe, M.; Izumi, H.; Ise, T.; Higuchi, S.; Yamori, T.; Yasumoto, K.; Kohno, K. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res. 2003, 63, 8592-8595.
35. Wakasugi, T.; Izumi, H.; Uchiumi, T.; Suzuki, H.; Arao, T.; Nishio, K.; Kohno, K. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007, 26, 5194-5203.
36. Igarashi, T.; Izumi, H.; Uchiumi, T.; Nishio, K.; Arao, T.; Tanabe, M.; Uramoto, H.; Sugio, K.; Yasumoto, K.; Sasaguri, Y.; et al.Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007, 26, 4749-4760.
37. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178-196.
38. Bailey, S.M.; Udoh, U.S.; Young, M.E. Circadian regulation of metabolism. J. Endocrinol. 2014, 222, R75-R96.
39. Yasuniwa, Y.; Izumi, H.; Wang, K.Y.; Shimajiri, S.; Sasaguri, Y.; Kawai, K.; Kasai, H.; Shimada, T.; Miyake, K.; Kashiwagi, E.; et al.Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway. PLoS ONE 2010, 5, e15330.
40. Izumi, H.; Wang, K.Y.; Morimoto, Y.; Sasaguri, Y.; Kohno, K. Circadian disruption and cancer risk: A new concept of stromal niche (review). Int. J. Oncol.2014, 44, 364-370.
41. Guaragnella, N.; Giannattasio, S.; Moro, L. Mitochondrial dysfunction in cancer chemoresistance. Biochem. Pharmacol. 2014, 92, 62-72.
42. Mizutani, S.; Miyato, Y.; Shidara, Y.; Asoh, S.; Tokunaga, A.; Tajiri, T.; Ohta, S. Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs. Cancer Sci. 2009, 100, 1680-1687.
43. Yao, Z.; Jones, A.W.; Fassone, E.; Sweeney, M.G.; Lebiedzinska, M.; Suski, J.M.; Wieckowski, M.R.; Tajeddine, N.; Hargreaves, I.P.; Yasukawa, T.; et al.PGC-1β mediates adaptive chemoresistance associated with mitochondrial DNA mutations. Oncogene 2013, 32, 2592-2600.
44. Guo, J.; Zheng, L.; Liu, W.; Wang, X.; Wang, Z.; Wang, Z.; French, A.J.; Kang, D.; Chen, L.; Thibodeau, S.N.; et al.Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer Res. 2011, 71, 2978-2987.
45. Campbell, C.T.; Kolesar, J.E.; Kaufman, B.A. Mitochondrial transcription factor A regulates mitochondrial transcription initiation, DNA packaging, and genome copy number. Biochim. Biophys. Acta 2012, 1819, 921-929.
46. Olivero, O.A.; Semino, C.; Kassim, A.; Lopez-Larraza, D.M.; Poirier, M.C. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat. Res. 1995, 346, 221-230.
47. See comment in PubMed Commons below Olivero, O.A.; Chang, P.K.; Lopez-Larraza, D.M.; Semino-Mora, M.C.; Poirier, M.C. Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat. Res. 1997, 391, 79-86.
48. Murakami, T.; Shibuya, I.; Ise, T.; Chen, Z.S.; Akiyama, S.; Nakagawa, M.; Izumi, H.; Nakamura, T.; Matsuo, K.; Yamada, Y.; et al.Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int. J. Cancer 2001, 93, 869-874.
49. Reshkin, S.J.; Greco, M.R.; Cardone, R.A. Role of pHi, and proton transporters in oncogene-driven neoplastic transformation. Philos. Trans. R. Soc. Lond. B 2014. 369, 20130100.
50. Yoshida, Y.; Hoshino, S.; Izumi, H.; Kohno, K.; Yamashita, Y. New roles of mitochondrial transcription factor A in cancer. J. Phys. Chem. Biophys. 2011, 1, 101.
51. Han, B.; Izumi, H.; Yasuniwa, Y.; Akiyama, M.; Yamaguchi, T.; Fujimoto, N.; Matsumoto, T.; Wu, B.; Tanimoto, A.; Sasaguri, Y.; et al.Human mitochondrial transcription factor A functions in both nuclei and mitochondria and regulates cancer cell growth. Biochem. Biophys. Res. Commun. 2011, 408, 45-51.
52. Altieri, D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8, 61-70.
53. Cory, S.; Adams, J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
54. Vaseva, A.V.; Moll, U.M. The mitochondrial p53 pathway. Biochim. Biophys. Acta 2009, 1787, 414-420.
55. Yoshida, Y.; Izumi, H.; Torigoe, T.; Ishiguchi, H.; Itoh, H.; Kang, D.; Kohno, K. P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res. 2003, 63, 3729-3734.
56. Wang, J.; Silva, J.P.; Gustafsson, C.M.; Rustin, P.; Larsson, N.G. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc. Natl Acad. Sci. USA 2001, 98, 4038-4043.
57. Ishiguchi, H.; Izumi, H.; Torigoe, T.; Yoshida, Y.; Kubota, H.; Tsuji, S.; Kohno, K. ZNF143 activates gene expression in response to DNA damage and binds to cisplatin-modified DNA. Int. J. Cancer 2004, 111, 900-909.
58. Izumi, H.; Yasuniwa, Y.; Akiyama, M.; Yamaguchi, T.; Kuma, A.; Kitamura, N.; Kohno, K. Forced expression of ZNF143 restrains cancer cell growth. Cancers 2011, 3, 3909-3920.
59. Izumi, H.; Wakasugi, T.; Shimajiri, S.; Tanimoto, A.; Sasaguri, Y.; Kashiwagi, E.; Yasuniwa, Y.; Akiyama, M.; Han, B.; Wu, Y.; et al.Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell-cycle-associated genes. Cancer Sci. 2010, 101, 2538-2545.
60. Kawatsu, Y.; Kitada, S.; Uramoto, H.; Li, Z.; Takeda, T.; Kimura, T.; Horie, S.; Tanaka, F.; Sasaguri, Y.; Izumi, H.; et al.The combination of strong expression of ZNF143 and high MIB-1 labelling index independently predicts shorter disease-specific survival in lung adenocarcinoma. Br. J. Cancer. 2014, 110, 2583-2592.
61. Takahashi, M.; Shimajiri, S.; Izumi, H.; Hirano, G.; Kashiwagi, E.; Yasuniwa, Y.; Wu, Y.; Han, B.; Akiyama, M.; Nishizawa, S.; et al.Y-box binding protein-1 is a novel molecular target for tumor vessels. Cancer Sci. 2010, 101, 1367-1373.
62. Wu, Y.; Wang, K.Y.; Li, Z.; Liu, Y.P.; Izumi, H.; Uramoto, H.; Nakayama, Y.; Ito, K.I.; Kohno, K. Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction. J. Exp. Clin. Cancer Res. 2014, 33, 112-117.
63. Wu, Y.; Wang, K.Y.; Li, Z.; Liu, Y.P.; Izumi, H.; Yamada, S.; Uramoto, H.; Nakayama, Y.; Ito, K.I.; Kohno, K. Y-box binding protein 1 expression in gastric cancer subtypes and association with cancer neovasculature. Clin. Transl. Oncol. 2015, 17, 152-159.
64. Kurita, T.; Izumi, H.; Kagami, S.; Kawagoe, T.; Toki, N.; Matsuura, Y.; Hachisuga, T.; Kohno, K. Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer. Cancer Sci. 2012, 103, 239-444.
65. Kimura, T.; Kitada, S.; Uramoto, H.; Li, Z.; Kawatsu, Y.; Takeda, T.; Horie, S.; Nabeshima, A.; Noguchi, H.; Sasaguri, Y.; et al.The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal adenocarcinoma. Histol. Histopathol. 2015, 30, 193-204.
66. Nakayama, Y.; Yamauchi, M.; Minagawa, N.; Torigoe, T.; Izumi, H.; Kohno, K.; Yamaguchi, K. Clinical significance of mitochondrial transcription factor A expression in patients with colorectal cancer. Oncol. Rep. 2012, 27, 1325-1330.
67. Yoshida, Y.; Hasegawa, J.; Nezu, R.; Kim, Y.K.; Hirota, M.; Kawano, K.; Izumi, H.; Kohno, K. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX. Cancer Sci. 2011, 102, 578-582.
68. Toki, N.; Kagami, S.; Kurita, T.; Kawagoe, T.; Matsuura, Y.; Hachisuga, T.; Matsuyama, A.; Hashimoto, H.; Izumi, H.; Kohno, K. Expression of mitochondrial transcription factor A in endometrial carcinomas: Clinicopathologic correlations and prognostic significance. Virchows Arch. 2010, 456, 387-393.
69. Burnett, J.C.; Rossi, J.J. RNA-based therapeutics: Current progress and future prospects. Chem. Biol. 2012, 19, 60-71.
70. Pirogova, E.; Istivan, T.; Gan, E.; Cosic, I. Advances in methods for therapeutic peptide discovery, design and development. Curr. Pharm. Biotechnol. 2011, 12, 1117-1127.